Patients and Survivors

自上一次CCSG审查以来，患者和幸存者计划领域已从12个成员扩大到19个成员 反映了癌症中心和机构支持的新招聘机会。同行审评共计 该计划领域的资金为1100万美元，其中300万美元（27%）来自国家癌症研究所。 研究所（自2002年以来，该方案领域的总供资增加了200万加元）。我们目前的癌症相关 出版物数量284（平均15/成员），其中30%在高影响力期刊，如JAMA， JNCI，临床肿瘤学杂志和临床癌症研究。方案内出版物有 从上一次审查时的15%增加到目前的40%，而计划间出版物仍保持不变， 大致相同（现在为8%，上次审查时为10%）。正如稍后所讨论的，我们现在有几个新的 资助赠款是跨计划和翻译研究合作的结果，在此期间， 我们预计，这将导致联合国系统各方案间出版物的增加， 下一轮赠款。只有少数治疗试验在PS程序区组合中代表;然而，我们 有许多患者被招募到干预和观察性非治疗性临床研究中， 从不同种族的人群中进行研究。

Since the past CCSG review, the Patients and Survivors Program Area has expanded from 12 to 19 members reflecting new recruitment opportunities supported by the Cancer Center and the Institution. Total peerreviewed funding for the program area is $11 million, including $3 million (27%) from the National Cancer Institute (overall funding for this Program Area has increased by $2 million since 2002). Our current cancerrelevant publications number 284 (average 15/member), with 30% in high impact journals such as JAMA, JNCI, the Journal of Clinical Oncology, and Clinical Cancer Research. Intra-programmatic publications have increased from 15% at last review to 40% currently, while inter-programmatic publications have remained about the same (8% now vs. 10% at last review). As is discussed later, we now have in place several new funded grants that are the result of inter-programmatic and translational research collaborations during this past funding period, and we expect that these will lead to an increase in inter-programmatic publications in the next grant cycle. Only a few therapeutic trials are represented in the PS Program Area portfolio; however, we have many patients who have been recruited to both intervention and observational non-therapeutic clinical research studies, from ethnically diverse populations.